期刊
JOURNAL OF TRANSLATIONAL AUTOIMMUNITY
卷 3, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.jtauto.2020.100069
关键词
Coronavirus; COVID-19; SARS-Cov-2; Convalescent plasma; Clinical trials; Randomized
类别
资金
- Universidad del Rosario [ABN-011]
- Bogota, Colombia
High expectations have been set around convalescent plasma (CP) for the treatment of COVID-19. However, none of the randomized controlled trials (RCTs) conducted so far have reached their primary endpoints. Herein we report that RCTs of CP disclose a high methodological variability in inclusion criteria, outcomes, appropriate selection of donors, dosage, concentration of neutralizing antibodies and times of transfusion. Therefore, at this time there is insufficient evidence to recommend for or against the use of CP as a treatment for COVID-19.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据